Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
On Thursday, Cantor Fitzgerald released a report detailing insights from a discussion with the CEO of Bio-Rad Laboratories (NYSE: BIO), a $6.2 billion life sciences company currently trading near its 52-week low. According to InvestingPro data, the company appears undervalued based on its Fair Value analysis. The conversation focused on the challenges facing the biotechnology sector, particularly in relation to drug pricing and industry innovation.
The report emphasized Bio-Rad Laboratories’ stance on the potential repercussions of lowering drug prices. The CEO expressed concerns that reducing drug prices could significantly impact the biotechnology ecosystem. With a healthy gross margin of 54% and strong liquidity position, as revealed by InvestingPro data, the company maintains a stable foundation despite these challenges. The report highlighted the company’s argument against the Most Favored Nation (MFN) model, suggesting it could shift the biotechnology hub to China, citing Europe’s experience with pharmaceutical pricing caps as a cautionary example.
The CEO also proposed several solutions, including reforming Pharmacy Benefit Managers (PBM), which could reduce U.S. list prices by 20-40%. Additional strategies mentioned were gradually increasing European drug prices and establishing direct-to-consumer channels.
The report noted that Bio-Rad Laboratories acknowledges the need for the biotechnology industry to compromise on pricing during negotiations to address the challenges it faces. The company remains committed to advocating for measures that protect innovation while navigating the complexities of global drug pricing.
In other recent news, Bio-Rad Laboratories Inc (NYSE:BIO). reported its financial results for the first quarter of 2025, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of $2.54, significantly higher than the forecasted $1.80, and reported revenue of $585.4 million, slightly above the anticipated $573.22 million. Despite a 4.2% year-over-year decline in net sales, Bio-Rad improved its non-GAAP operating margin to 10.8% from 9.7% in the same quarter last year. The company continues to invest in innovative product development, although concerns about potential reductions in academic research funding remain. Bio-Rad’s acquisition of Stila Technology is on track to close by the end of the third quarter, which is expected to enhance its digital PCR offerings. The company has also been proactive in implementing strategies to mitigate the impact of global trade disruptions and tariffs. Bio-Rad projects full-year currency-neutral revenue growth between -1% and +1.5%, with a particular focus on its Life Science and Diagnostics businesses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.